Get the Stockscreener App
1.50
12.78%
0.17
After Hours:
1.50
NanoViricides Inc stock is traded at $1.50, with a volume of 594.02K.
It is up +12.78% in the last 24 hours and up +8.70% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.33
Open:
$1.32
24h Volume:
594.02K
Relative Volume:
0.70
Market Cap:
$34.47M
Revenue:
-
Net Income/Loss:
$-8.09M
P/E Ratio:
-3.4451
EPS:
-0.4354
Net Cash Flow:
$-7.37M
1W Performance:
+9.49%
1M Performance:
+8.70%
6M Performance:
+17.19%
1Y Performance:
+8.70%
1-Day Range:
$1.31
$1.545
1-Week Range:
$1.30
$1.545
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.50 | 31.72M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
FDA rare pediatric disease designation could speed a measles drug review - Stock Titan
[EFFECT] NANOVIRICIDES, INC. SEC Filing - Stock Titan
NanoViricides, Inc. Actuals & Estimates (MUN:NV3P) - TradingView
NanoViricides, Inc. Actuals & Estimates (AMEX:NNVC) - TradingView
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides, Inc. Actuals & Estimates (LS:A2PSNF) - TradingView
NNVC Forecast — Price Target — Prediction for 2027 - TradingView
A2PSNF Forecast — Price Target — Prediction for 2027 - TradingView
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Yahoo Finance
NanoViricides Inc (NNVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Ships NV-387 to DRC for Phase II MPox Trial - MEXC
NanoViricides sends oral NV-387 to Congo for Phase II trial prep - Stock Titan
NanoViricides Inc (NNVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Inc (NNVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan
NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com
NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate
NanoViricides (NNVC) Retreats 4.3%, Nears Critical Support at $1.69AAII Bullish - thelegaladvocate.com
Ebola Global Health Emergency Needs a Broad-Spectrum DrugNV-387 is a Strong Potential Candidate, Says NanoViricides - ACCESS Newswire
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
Nanoviricides(NNVC) Stock Options Chain | Quotes & News - Moomoo
NanoViricides (NNVC) Surges 15.9% as Speculative Buying Drives Shares Above $1.75MA Cross Alert - The Legal Advocate
NanoViricides (NNVC) Surges 13.6% as Stock Approaches Key ResistanceSwing Trade Setups - The Legal Advocate
NNVC Stock Gains Attention As NV-387 Targets Ebola And Measles - StocksToTrade
NNVC Stock Draws Traders As NV-387 Targets Ebola, Measles - timothysykes.com
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - ACCESS Newswire
NNVCNanoViricides Inc Stock Price and Quote - Finviz
Contact | Statesman-Examiner - FinancialContent
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
NanoViricides Inc. (NNVC) Q1 2026 Earnings: Narrower Loss Drives Positive Stock ReactionEarnings Beat Streak - newsline.com
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NanoViricides, Inc - Reuters
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):